Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells

Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its downstream activation of pro-apoptotic transcriptional programs. Inhibitors of <i>DUX4</i> expression have the potential to treat F...

Full description

Bibliographic Details
Main Authors: Christopher D. Sarsons, Dean Gilham, Laura M. Tsujikawa, Sylwia Wasiak, Li Fu, Brooke D. Rakai, Stephanie C. Stotz, Agostina Carestia, Michael Sweeney, Ewelina Kulikowski
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Biomedicines
Subjects:
facioscapulohumeral muscular dystrophy
FSHD
DUX4
bromodomain and extra-terminal domain
BET inhibitor
transcriptome
Online Access:https://www.mdpi.com/2227-9059/11/10/2683

Internet

https://www.mdpi.com/2227-9059/11/10/2683

Similar Items